Technology
Health
Biotechnology

Cyclacel Pharmaceuticals

$1.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.14 (15.86%) Today
+$0.01 (1.00%) After Hours

Why Robinhood?

You can buy or sell CYCC and other stocks, options, ETFs, and crypto commission-free!

About

Cyclacel Pharmaceuticals, Inc. Common Stock, also called Cyclacel Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products includes CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Employees
12
Headquarters
Berkeley Heights, New Jersey
Founded
1996
Market Cap
10.36M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
184.43K
High Today
$1.03
Low Today
$0.855
Open Price
$0.87
Volume
1.17M
52 Week High
$1.87
52 Week Low
$0.51

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Cancer Prevention
Pharmaceutical
US

News

Simply Wall StMar 12

Should You Be Pleased About The CEO Pay At Cyclacel Pharmaceuticals, Inc.’s (NASDAQ:CYCC)

Spiro Rombotis became the CEO of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in 1997. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then we’ll look at a snap shot of the business growth. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. This method should give us information to assess how appropriately the company pays the CEO. Check out our latest...

391

Earnings

-$0.50
-$0.30
-$0.09
$0.11
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
Available Mar 27, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.